CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 136 enrolled
Drug / intervention
GORE® VIAFORT Vascular Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05409976
NCT05409976N/AActive
CompareCT.gov

Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction With or Without Combined Iliofemoral Obstruction

W.L.Gore & Associates·interventional·Posted Jun 8, 2022·Updated Apr 29, 2026

In Brief

A clinical study evaluating GORE® VIAFORT Vascular Stent for Venous Thromboses and 9 related conditions. Active but no longer recruiting, targeting 136 participants across 17 sites in 7 countries.

Detailed Summary

This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
CountriesAustralia, Germany, Ireland, Italy, New Zealand, United Kingdom, United States
Collaborators--

Timeline

N/AActive
20232024202520262027202820292030
First PostedJun 8, 2022
Enrollment StartOct 25, 2022
Primary CompletionMay 9, 2026
Study CompletionMay 9, 2030
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 4.1 years ago

Interventions

GORE® VIAFORT Vascular Stentdevice

Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.